skip to Main Content

Welcome

Celebrating 80 Years Of Service!

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Advance the comprehensive management of allergy and inflammatory disease in Otolaryngology-Head and Neck Surgery through training, education, and advocacy."

ADVOCACY UPDATES

Changes To E/M Codes Beginning On January 1st

Effective January 1, 2021, the Centers for Medicare & Medicaid (CMS) finalized significant changes to…

read more

Additional COVID-19 Relief Up in the Air

House Speaker Nancy Pelosi (D-CA) and Treasury Secretary Steven Mnuchin appeared to be moving closer…

read more

CY 2021 Physician Fee Schedule Proposed Rule Summary

On August 3, the Centers for Medicare & Medicaid Services (CMS) released the Medicare Physician…

read more

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

04/01/21: Fellow Exam Application Deadline
Learn more

06/01/21: Research Grant Cycle
Learn more

06/26/21: Membership Application Deadline to be eligible for AAOA Member rate for the 2021 Basic Course

08/01/21:Scientific Abstract Submission Deadline
Learn More

09/01/21: Membership Application Deadline to be voted in at the 2021 Annual Meeting

12/01/21: Research Grant Cycle
Learn more

EDUCATION

Our 2021 AAOA Basic Course in Allergy & Immunology will be launched June 1st: Over 11 hrs of pre-learning, on-demand will set you up to gain the full value of our curriculum and engage in the live-stream session.

Live Stream July 8-11 will offer unique learning formats to offer learners the core concepts of allergy diagnosis and management. Join us and test your pre-work efforts for our Immunology & Pharmacotheapy Trivia Slams; Great Debates on Environmental Controls; Allergen Testing Panel “Bake Off,” Late Night with Dr. Levy, AAOA’s Escape Room Expedition, Hands On Testing and Dose Calculation Practica, Office Tours, and more.

Structured for otolaryngologists integrating more allergy assessment and management into their practice, AAOA members providing specialized allergy care who need to remain current with literature-based evidence and practice trends, residents, PA/NPs who work in otolaryngology, and allied health staff who support their physicians in the management of allergic patients. The Basic Course offers unique opportunities to learn the state of the art in allergy patient care. Learn More

IFAR

Available Now

IFAR Impact Factor: 2.454

aaoaf-ifar

IFAR Featured Content: COVID-19 - Free Access
Endonasal instrumentation and aerosolization risk in the era of COVID‐19: simulation, literature review, and proposed mitigation strategies . Read More

Changes in Managing Practices

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2021 Basic Course in Allergy & Immunology
On-demand June 1; Live Stream July 8-11 | Virtual
Learn More and Register

USP 797 Online Module
Learn More and Register

2021 AAOA Annual Meeting
Pre-launch Mid-September
Live Stream Starting on Oct 16 | Virtual
Learn More

News and Updates

2021 AAOA Annual Meeting – Scientific Abstracts Submissions Now Open

Have novel research tied to allergy, inflammatory disease in ENT, comprehensive management of allergy and…

read more

Congress Sends Sesame Labeling Bill To President

By Beth Wang / April 15, 2021 at 11:57 AM The House on Wednesday (April 14) passed…

read more
College Allergy Symptoms Treatment Back to Shcool

PRACTICE RESOURCES

AAOA Practice Resource Tool Kit

The American Academy of Otolaryngic Allergy (AAOA) Practice Resource Tool Kit is intended as a guide to help AAOA members integrate allergy into their otolaryngology practice and to continually improve on this integration as new information, regulations, and resources become available.

Read More

PATIENT CORNER

What Type Of Immunotherapy Is Right For Me?

By Jodi Zuckerman MD, FAAOA

Currently there are three forms of immunotherapy.  After skin testing or blood testing, reactivity can be quantified to a specific allergen such as grass, dust mite, cat, ragweed.  Immunotherapy is the process of presenting these antigens in a safe manner to the body to build protective antibodies overtime that could block the possible cascade of allergy symptoms when that allergen is presented.  Immunotherapy is usually continued to 3-5 years with all forms currently available.  Most physicians will want patients to have a plan to carry epi-pens while on immunotherapy. 

Subcutaneous Immunotherapy (SCIT)

Subcutaneous immunotherapy is classic allergy shots.  Vials are mixed with a small amount of the appropriate concentration of allergens that were determined significant based on the patient’s historical symptoms and positives on blood or skin testing.  Usually shots will start 1-2x per week and extend out over time to monthly.  The goal is to slowly elevate the amount of the allergen overtime to a maintenance dose. This requires weekly office visits. This form of immunotherapy is covered by most insurance carriers.  While severe systemic reactions are very rare, there is a higher risk of systemic reactions with this type of immunotherapy.

Sublingual Immunotherapy (SLIT)

Sublingual immunotherapy is a newer concept but variation on the same concepts as SCIT. With this form of immunotherapy, allergens are mixed in a vial and applied under the tongue as drops. This form of immunotherapy can address multiple allergens. The build-up to maintenance is very quick, and patients are able to escalate without the need to come into the office weekly. Most patients will do their first trial in the office and then complete their treatment on their own, checking in with their physicians every few months.  The risk of severe reactions is lower with SLIT.  This is sometimes a better alternative to shots for patients with needle phobia, children, and those that travel or cannot come in weekly for shots.  It is usually not covered by insurance and is an out of pocket expense.

Sublingual Tablets: Odactra, Grastek, Oralair, Ragwitek

Sublingual tablets are a form of sublingual immunotherapy in a dissolvable pill formation.  These tablets are FDA approved and are covered by many insurance companies.  Currently there are tablets available for allergy to dust mite, grass pollen, and ragweed. This form of immunotherapy addresses one antigen, but tablets are sometimes used in combination. The duration is the same as traditional immunotherapy and dosing is usually daily for the year or 12 weeks before and through the season of the allergen.  Studies have shown risks similar to sublingual immunotherapy and these are generally well tolerated.  

Which type of immunotherapy is best for patients is a joint decision between the patient and treating physician.  Many factors are considered including availability to come to the office, tolerance of shots, financial considerations, and comfort with safety profiles.  The allergy profile and patient preference will determine the best course of treatment. 

Back To Top